Mesoblast Limited (MSB) is a Company that is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in reduction of the damaging inflammatory process.
Find out what a historical investment in Mesoblast Limited would be worth today using our MSB stock calculator.
Buying MSB shares in Australia can be done through an online investing platform, such as Stake. Follow the simple steps below to start investing in Mesoblast Limited in minutes.
Sign up with some I.D. and zero paperwork
Add funds to your account
Make your first investment in MSB
What is the ticker symbol of Mesoblast Limited?
The ticker symbol for Mesoblast Limited is MSB.
How much is one share of MSB?
One share of MSB is valued at $1.70 as of 22 November 2026.
What is the market capitalisation of Mesoblast Limited MSB?
As of 22 November 2026 Mesoblast Limited has a market cap of $2.2B.
What is the P/E ratio of MSB?
The Price to Earnings ratio of MSB is -26.39.
What is the Earnings Per Share of MSB?
The Earnings Per Share of MSB is -$0.06.
What is the 52-week high for Mesoblast Limited stock?
The Mesoblast Limited 52-week high stock price is $3.31.
What is the 52-week low for Mesoblast Limited stock?
The Mesoblast Limited 52-week low stock price is $1.68.
Can I buy MSB shares through Stake, an investing platform like CommSec, Selfwealth or Superhero?
Yes, the Stake investing platform allows you to buy MSB shares and over 13,000 more stocks and ETFs across the ASX and Wall St.
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.